Forum

When might consumer surveys provide a more accurate picture of product substitutability than typical market share measures in merger reviews? Why are “no-poach” clauses in franchise agreements drawing increasing scrutiny from antitrust regulators? How are data science tools being used to predict the onset of a particularly difficult-to-diagnose autoimmune disorder?

How can the power of data science be harnessed to create effective controls against the diversion of opioids and other controlled substances, or to predict whether a disputed patent will survive a challenge? What are the legal and regulatory implications of multi-sided platforms, where behavior that some see as anticompetitive may in fact enhance consumer welfare?

This issue of Forum demonstrates the broad scope and deep impact of Analysis Group’s ongoing work on behalf of our clients. We continue to use leading-edge methodologies and analysis to tackle issues across virtually every sector in the landscape of economic and litigation consulting.　　　　　　　　　　　　　　　　 　　　　　　　　　　　　　　　　　　　　　　

In this issue, we highlight examples of our work both in and out of the courtroom. Statistical modeling was our assignment in the high-profile NFL “Deflategate” matter. Intellectual property work continued to expand, both in the context of the tools applied – such as the growing reliance on market research – and with respect to evaluating significant changes in the patent enforcement system.

In the past year, Analysis Group has helped our clients address increasingly complex needs. As we continue to expand our professional staff, we are also proud of our network of affiliated academic experts, who provide invaluable direction with state-of-the-art approaches to address complex financial and economic issues. 　　　　　　　　　　　　　　　　 　　　　　　

This issue of Forum showcases a diverse set of matters that our firm has recently worked on, including false advertising claims, class certification, criminal price-fixing, and securities-lending cases. The scope and complexity of these engagements, and the opportunities they provide our teams to work with experts from academia and industry, are a significant part of what attracts top people to our firm.

More than 80% of best-selling drugs have been exposed to some form of safety-related litigation over the past decade. The risk of adverse events from some on-market drugs is serious, and the use of prescription medications in the U.S. is increasing. What is required – and often missing – in the examination of drug safety claims is a comprehensive understanding of the drug in question.

For the second year in a row, Analysis Group was ranked the best large firm in Massachusetts in the Boston Globe’s Top Places to Work poll. This recognition is incredibly gratifying. We achieved this through an enduring focus not only on what we do, but on how we do it – by reinforcing a culture of respect, collaboration, and opportunity for the people who work here.